LARIMAR THERAPEUTICS INC (LRMR)
US5171251003 - Common Stock
LARIMAR THERAPEUTICS INC
NASDAQ:LRMR (12/18/2024, 11:47:05 AM)
4.115
-0.21 (-4.75%)
Company Profile
Larimar Therapeutics, Inc. Is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics mitochondrial disorders and Friedreich's ataxia. The company is headquartered in Bala Cynwyd, Pennsylvania and currently employs 42 full-time employees. The company went IPO on 2014-06-19. The firm is focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide (CPP) technology platform. The Company’s lead product candidate, nomlabofusp, is a subcutaneously administered, recombinant fusion protein intended to deliver tissue frataxin (FXN), an essential protein, to the mitochondria of patients with Friedreich's ataxia (FA). FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality. Its CPP platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets, has the potential to enable the treatment of other rare and orphan diseases. The company intends to use its proprietary platform to target additional orphan indications characterized by deficiencies in or alterations of intracellular content or activity.
Company Info
LARIMAR THERAPEUTICS INC
Three Bala Plaza East. Suite 506
Bala Cynwyd PENNSYLVANIA 19004
P: 18445119056
CEO: Carole Ben-Maimon
Employees: 42
Website: https://larimartx.com/
LRMR News
2 days ago - Market News VideoNoteworthy Monday Option Activity: AOSL, BIRK, LRMR
2 days ago - ChartmillHere are the top movers in Monday's session, showcasing the stocks with significant price changes.These stocks are moving in today's session
2 days ago - ChartmillLet's take a look at the stocks that are in motion in today's session.Let's have a look at what is happening on the US markets in the middle of the day on Monday. Below you can find the top gainers and losers in today's session.
2 days ago - Yahoo FinanceWhy Is Larimar Therapeutics Stock Trading Lower On Monday?On Monday, Larimar Therapeutics, Inc. (NASDAQ:LRMR) released initial data from the ongoing long-term OLE study evaluating daily subcutaneous injections of 25 mg of nomlabofusp self-administered or administered by a caregiver in participants with Friedreich’s Ataxia. Friedreich’s Ataxia is caused by a mutation in the FXN gene, which carries the code for the frataxin protein. Frataxin is important for the normal function of mitochondria, the energy-producing parts of cells At the time of data cut
2 days ago - ChartmillThe market is buzzing with gapping stocks on Monday. Let's uncover which stocks are experiencing notable gaps during today's session.Which stocks are gapping on Monday?
2 days ago - Larimar TherapeuticsLarimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Study & Progress Across Nomlabofusp Program for Friedreich’s AtaxiaDaily subcutaneous injections of 25 mg nomlabofusp in 14 participants were generally well tolerated for up to 260 days in the ongoing open label extension...
LRMR Twits
Here you can normally see the latest stock twits on LRMR, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
